📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-29 00:00
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
65 announcements match the current filters (relevance ≥ 5).
Anupam Rasayan Takes Majority Control (50.07%) in Bliss GVS Pharma via ₹162.7 Cr Market Buy & SPA
Anupam Rasayan has acquired controlling stake and promoter status in Bliss GVS Pharma Limited, reaching a combined 50.07% holding (5,32,36,264 shares) alongside its PAC on September 28, 2026. This follows the completion of the SPA for 47.95% (5,09,84,595 shares) and an additional on-market purchase of 22,50,000 shares (2.12%) for an aggregate cash consideration of ₹162.74 crore at ₹723.29 per share. Bliss GVS reported FY26 turnover of ₹798.98 crore (down from ₹1,000.64 crore in FY24) and net worth of ₹1,231.76 crore. The strategic acquisition extends Anupam Rasayan forward into finished dosage formulations and global pharma markets.
Confidence: HIGH
What changedAnupam Rasayan completed the acquisition under the SPA and additional market purchases, crossing 50.07% ownership and officially becoming the promoter of Bliss GVS Pharma.
Why it mattersAdds ~₹800 crore of pharma revenue (~31% of Anupam's TTM revenue of ₹2,535 crore) and forwards integrates the business from specialty chemical intermediates into finished formulations.
Total stake acquired (with PAC): 50.07%On-market consideration: INR 162,73,98,675.00Acquisition price per share: Rs. 723.2883Target FY26 turnover: Rs. 798,98,23,000Bliss FY26 revenue vs Anupam TTM revenue: ~31.5%
📅 Short termStock reaction will reflect the formal takeover of Bliss GVS and the cash deployment of ₹162.74 cr for the recent market tranche.
📈 Long termExpands Anupam's capability into finished dosage forms across 60+ countries, but integration execution is critical as Bliss GVS revenue declined from ₹1,000.6 cr in FY24 to ₹798.98 cr in FY26.
⚠ Risk flags
- Target company Bliss GVS revenue has contracted over the last two years (from ₹1,000.6 cr in FY24 to ₹798.98 cr in FY26)
- Integration risks entering downstream finished formulations
Key Highlights
Anupam Rasayan and PAC acquired 50.07% stake (5,32,36,264 shares) taking full promoter control of Bliss GVS Pharma.
SPA completed for 5,09,84,595 shares (47.95%) plus 22,50,000 shares (2.12%) acquired via on-market purchase on 28 September 2026.
Market acquisition completed for ₹162.74 crore in cash at ₹723.2883 per share.
Target company Bliss GVS Pharma reported FY26 turnover of ₹798.98 crore and net worth of ₹1,231.76 crore as on March 31, 2026.
👀 What to Watch
Track the integration timeline, consolidation of Bliss GVS financials into Anupam Rasayan's quarterly P&L, and management commentary regarding margin impacts and pharma synergies.
Anupam Rasayan Completes 48.2% Stake Acquisition in Bliss GVS Pharma at ₹299/Share
Anupam Rasayan has concluded the acquisition of a 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share via its subsidiary Mates Visa Consultancy, completing its open offer process. The transaction was funded through a ₹300 crore term loan and ~₹1,450 crore via non-controlling, non-voting instruments led by Bain Capital, Trust Group, and Investec. Bliss GVS adds ₹927 crore in revenue to create a combined pro-forma platform exceeding ₹4,000 crore in revenue and ~₹834 crore in EBITDA. Bliss GVS facilities currently run at ~30% capacity utilisation, providing operating leverage for forward integration into finished dosage formulations.
Confidence: HIGH
What changedAnupam Rasayan finalized payment and completed the acquisition of a 48.2% controlling stake in formulations maker Bliss GVS Pharma.
Why it mattersExtends Anupam Rasayan forward from specialty chemicals and intermediates into finished formulations, scaling group pro-forma revenue to over ₹4,000 crore (~1.6x of TTM revenue).
Acquisition stake: 48.2%Acquisition price per share: ₹299Debt funded: ₹300 croreInvestor instrument funding: ~₹1,450 croreCombined pro-forma revenue: >₹4,000 croreBliss GVS pro-forma revenue vs TTM revenue: ~36.6%
📅 Short termMarket sentiment should react positively to the formal closing of the transaction and integration into consolidated financials without excessive balance-sheet leverage.
📈 Long termCreates an end-to-end integrated platform spanning fluorination raw materials (Tanfac), US CDMO footprint (Jayhawk), and finished formulations (Bliss GVS) with substantial unutilized formulation capacity.
⚠ Risk flags
- Integration execution risks across cross-border and cross-sector operations
- Low existing capacity utilization (30%) requiring active commercialization
- Servicing of non-controlling financial instruments
Key Highlights
Acquired 48.2% controlling stake in Bliss GVS Pharma at ₹299 per share (~24x LTM earnings)
Funding structured via ₹300 crore term loan and ~₹1,450 crore in non-voting instruments led by Bain Capital
Combined pro-forma platform revenue projected at >₹4,000 crore and EBITDA of ~₹834 crore
Bliss GVS brings ₹927 crore pro-forma revenue and 6 facilities operating at ~30% capacity utilisation
👀 What to Watch
Track the upcoming quarterly consolidated results to monitor the margin impact of Bliss GVS integration and assess ramp-up from its current 30% capacity utilisation.
Anupam Rasayan guarantees ₹300 Cr NCD issue for subsidiary MVCPL to fund Bliss GVS Pharma stake
Anupam Rasayan has executed security documents including an unconditional corporate guarantee and share pledges to back up to ₹300 crore unlisted NCDs issued by its wholly-owned subsidiary, Mates Visa Consultancy Private Limited (MVCPL). The debt carries a maximum tenor of 48 months and will fund MVCPL's acquisition of securities of Bliss GVS Pharma Limited. The company has also pledged 100% of its equity in MVCPL and its 15% stake in Purebliss Pharma Solutions, alongside granting Purebliss a distress call option on MVCPL equity for ₹1.00 upon default.
Confidence: HIGH
What changedAnupam Rasayan formalized security documents, executing a corporate guarantee and share pledges for a ₹300 crore NCD issue by its subsidiary MVCPL.
Why it mattersThe ₹300 crore guarantee adds contingent liability to Anupam Rasayan (representing ~19% of existing debt of ₹1,574 crore), creating structural exposure to third-party acquisition financing.
NCD Issue Size: INR 300,00,00,000NCD Tenor: 48 monthsCall Option Consideration: INR 1.00Issue size vs Existing Debt: ~19.1%Issue size vs TTM Revenue: ~11.8%
📅 Short termNeutral to cautious trading response as the market evaluates the risks associated with the ₹300 crore corporate guarantee and distressed call option structure.
📈 Long termStrategic integration and capital allocation will depend on the performance of the underlying Bliss GVS Pharma investment, though Anupam Rasayan carries downside contingent risk if MVCPL defaults.
⚠ Risk flags
- Contingent financial liability of up to ₹300 crore via unconditional corporate guarantee
- Pledge of 100% MVCPL equity and 15% Purebliss equity
- Distress call option exercisable by Purebliss at ₹1.00 in event of financing default
Key Highlights
MVCPL to issue up to ₹300 crore senior, secured, unrated, unlisted, redeemable NCDs (up to 30,000 NCDs of ₹1,00,000 face value)
Proceeds will be used by MVCPL for acquiring securities of Bliss GVS Pharma Limited
Maximum tenor of the debentures is 48 months from the deemed date of allotment
Anupam Rasayan pledged 100% of MVCPL equity and its 15% stake in Purebliss as security
Company granted Purebliss a call option to acquire 100% of MVCPL for ₹1.00 under default trigger events
👀 What to Watch
Monitor disclosures around MVCPL's acquisition of Bliss GVS Pharma securities and track any potential strain on Anupam Rasayan's consolidated leverage given the ₹300 crore contingent liability.
Anupam Rasayan guarantees ₹300 Cr NCD issue for subsidiary MVCPL to fund Bliss GVS Pharma stake
Anupam Rasayan has executed security documents including an unconditional corporate guarantee and share pledges to back up to ₹300 crore unlisted NCDs issued by its wholly-owned subsidiary, Mates Visa Consultancy Private Limited (MVCPL). The debt carries a maximum tenor of 48 months and will fund MVCPL's acquisition of securities of Bliss GVS Pharma Limited. The company has also pledged 100% of its equity in MVCPL and its 15% stake in Purebliss Pharma Solutions, alongside granting Purebliss a distress call option on MVCPL equity for ₹1.00 upon default.
Confidence: HIGH
What changedAnupam Rasayan formalized security documents, executing a corporate guarantee and share pledges for a ₹300 crore NCD issue by its subsidiary MVCPL.
Why it mattersThe ₹300 crore guarantee adds contingent liability to Anupam Rasayan (representing ~19% of existing debt of ₹1,574 crore), creating structural exposure to third-party acquisition financing.
NCD Issue Size: INR 300,00,00,000NCD Tenor: 48 monthsCall Option Consideration: INR 1.00Issue size vs Existing Debt: ~19.1%Issue size vs TTM Revenue: ~11.8%
📅 Short termNeutral to cautious trading response as the market evaluates the risks associated with the ₹300 crore corporate guarantee and distressed call option structure.
📈 Long termStrategic integration and capital allocation will depend on the performance of the underlying Bliss GVS Pharma investment, though Anupam Rasayan carries downside contingent risk if MVCPL defaults.
⚠ Risk flags
- Contingent financial liability of up to ₹300 crore via unconditional corporate guarantee
- Pledge of 100% MVCPL equity and 15% Purebliss equity
- Distress call option exercisable by Purebliss at ₹1.00 in event of financing default
Key Highlights
MVCPL to issue up to ₹300 crore senior, secured, unrated, unlisted, redeemable NCDs (up to 30,000 NCDs of ₹1,00,000 face value)
Proceeds will be used by MVCPL for acquiring securities of Bliss GVS Pharma Limited
Maximum tenor of the debentures is 48 months from the deemed date of allotment
Anupam Rasayan pledged 100% of MVCPL equity and its 15% stake in Purebliss as security
Company granted Purebliss a call option to acquire 100% of MVCPL for ₹1.00 under default trigger events
👀 What to Watch
Monitor disclosures around MVCPL's acquisition of Bliss GVS Pharma securities and track any potential strain on Anupam Rasayan's consolidated leverage given the ₹300 crore contingent liability.
Anupam Rasayan Allots ₹145 Cr Unlisted NCDs at 10.25% Coupon to Aditya Birla Capital
Anupam Rasayan India Limited has allotted 14,500 unlisted, secured non-convertible debentures (NCDs) aggregating to ₹145 crore on a private placement basis to Aditya Birla Capital Limited. The debentures carry an interest coupon rate of 10.25% per annum for a total tenure of 13 months, maturing on October 21, 2027. Most of the principal (₹99,500 per ₹1,00,000 NCD, or ~₹144.28 crore) is scheduled for early partial redemption by October 21, 2026. The borrowing is secured by hypothecation of an escrow account and a pledge of promoter shares, with proceeds targeted for debt repayment, group investments, or general corporate purposes.
Confidence: HIGH
What changedThe company issued and allotted ₹145 crore of 13-month unlisted NCDs on private placement to Aditya Birla Capital.
Why it mattersThe borrowing accounts for ~9.2% of total debt (₹1,574 Cr) and provides liquidity for debt refinancing or group company investments, though at a relatively high coupon of 10.25% and requiring promoter share pledging.
Issue size: INR 145,00,00,000Issue vs Total Debt: ~9.2%Coupon rate: 10.25% p.a.Tenure: 13 monthsPartial redemption date: 21 October 2026
📅 Short termShort-term impact is neutral given the standard refinancing nature, though the fast redemption schedule by October 2026 implies quick cash turnaround.
📈 Long termLimited structural impact on leverage since proceeds are largely meant for refinancing existing debt facilities.
⚠ Risk flags
- High coupon rate of 10.25% p.a. on short-term borrowing
- Creation of pledge over promoter shares as part of the security package
Key Highlights
Allotment of 14,500 senior secured unlisted NCDs aggregating to ₹145 crore
Issued on private placement to Aditya Birla Capital Limited at a 10.25% p.a. coupon rate
Short-term structured redemption: ₹99,500 per ₹1,00,000 face value repayable on or before October 21, 2026, and the remaining ₹500 on October 21, 2027
Secured by a first-ranking pledge over identified promoter shares and hypothecation of an Axis Bank escrow account
👀 What to Watch
Track disclosures regarding the execution and extent of the promoter share pledge, as well as the upcoming October 2026 partial repayment.
Anupam Rasayan to Raise ₹160 Cr via Unlisted NCDs at 10.25% Coupon
Anupam Rasayan's board has approved the private placement of up to 16,000 secured, rated, unlisted redeemable non-convertible debentures (NCDs) aggregating to ₹160 crore to Aditya Birla Capital Limited. The debentures carry a 10.25% p.a. coupon rate and have an unusual redemption structure: ₹99,500 per ₹1,00,000 face value is due within one month (on or before October 21, 2026), with the residual ₹500 redeemable on October 21, 2027. The issuance is secured by promoter share pledges and an escrow charge. Relative to existing total debt of ₹1,574 crore, the ₹160 crore issue represents roughly 10.2% of debt, aimed at refinancing existing debt, group company investments, or general corporate purposes.
Confidence: HIGH
What changedThe company approved the issuance of ₹160 crore unlisted NCDs to Aditya Birla Capital with a pledge of promoter-held shares.
Why it mattersThe ₹160 crore borrowing adds short-term liquidity at 10.25% for debt repayment or group investments, representing ~10.2% of its ₹1,574 crore total debt load, but introduces promoter share encumbrance.
Issue size: ₹160 croreCoupon rate: 10.25% p.a.Issue size vs Existing Debt: ~10.2%First redemption per NCD (due 21 Oct 2026): ₹99,500Final maturity date: 21 October 2027
📅 Short termBorrowing terms require an immediate major repayment of ₹99,500 per debenture within a month, making it effectively bridge financing with near-term liquidity commitments.
📈 Long termLimited structural impact given the small scale relative to market cap (₹22,659 Cr) and net worth (₹3,235 Cr), though promoter encumbrance is a minor governance factor to monitor.
⚠ Risk flags
- Promoter share pledge created as primary security for the debt.
- Aggressive near-term cash outflow needed with 99.5% principal redemption due in October 2026.
Key Highlights
Board approved issuance of 16,000 NCDs aggregating up to ₹160 crore at ₹1,00,000 face value per debenture.
Coupon rate fixed at 10.25% p.a. payable along with principal redemptions.
Unusual redemption schedule: ₹99,500 per NCD payable by October 21, 2026, and remaining ₹500 payable on October 21, 2027.
Secured by a first-ranking pledge over company shares held by promoter family members and a charge over an Axis Bank escrow account.
Entire issue is on a private placement basis to Aditya Birla Capital Limited.
👀 What to Watch
Track the execution of the promoter share pledge agreements and watch upcoming Q2 FY27 interest costs to see whether this short-term borrowing replaces higher-cost debt.
Anupam Rasayan to Raise ₹160 Cr via Unlisted NCDs at 10.25% Coupon
Anupam Rasayan's board has approved the private placement of up to 16,000 secured, rated, unlisted redeemable non-convertible debentures (NCDs) aggregating to ₹160 crore to Aditya Birla Capital Limited. The debentures carry a 10.25% p.a. coupon rate and have an unusual redemption structure: ₹99,500 per ₹1,00,000 face value is due within one month (on or before October 21, 2026), with the residual ₹500 redeemable on October 21, 2027. The issuance is secured by promoter share pledges and an escrow charge. Relative to existing total debt of ₹1,574 crore, the ₹160 crore issue represents roughly 10.2% of debt, aimed at refinancing existing debt, group company investments, or general corporate purposes.
Confidence: HIGH
What changedThe company approved the issuance of ₹160 crore unlisted NCDs to Aditya Birla Capital with a pledge of promoter-held shares.
Why it mattersThe ₹160 crore borrowing adds short-term liquidity at 10.25% for debt repayment or group investments, representing ~10.2% of its ₹1,574 crore total debt load, but introduces promoter share encumbrance.
Issue size: ₹160 croreCoupon rate: 10.25% p.a.Issue size vs Existing Debt: ~10.2%First redemption per NCD (due 21 Oct 2026): ₹99,500Final maturity date: 21 October 2027
📅 Short termBorrowing terms require an immediate major repayment of ₹99,500 per debenture within a month, making it effectively bridge financing with near-term liquidity commitments.
📈 Long termLimited structural impact given the small scale relative to market cap (₹22,659 Cr) and net worth (₹3,235 Cr), though promoter encumbrance is a minor governance factor to monitor.
⚠ Risk flags
- Promoter share pledge created as primary security for the debt.
- Aggressive near-term cash outflow needed with 99.5% principal redemption due in October 2026.
Key Highlights
Board approved issuance of 16,000 NCDs aggregating up to ₹160 crore at ₹1,00,000 face value per debenture.
Coupon rate fixed at 10.25% p.a. payable along with principal redemptions.
Unusual redemption schedule: ₹99,500 per NCD payable by October 21, 2026, and remaining ₹500 payable on October 21, 2027.
Secured by a first-ranking pledge over company shares held by promoter family members and a charge over an Axis Bank escrow account.
Entire issue is on a private placement basis to Aditya Birla Capital Limited.
👀 What to Watch
Track the execution of the promoter share pledge agreements and watch upcoming Q2 FY27 interest costs to see whether this short-term borrowing replaces higher-cost debt.
Anupam Rasayan to guarantee ₹300 Cr NCDs for subsidiary Mates Visa and pledge shares
Anupam Rasayan's board approved providing an unconditional and irrevocable corporate guarantee for up to ₹300 crore of senior secured unlisted NCDs to be issued by its wholly-owned subsidiary, Mates Visa Consultancy Private Limited (MVCPL). The company will also pledge 100% of its equity holding in MVCPL and grant a call option to Purebliss Pharma Solutions Private Limited to acquire MVCPL. Additionally, Anupam Rasayan approved pledging its entire 15% equity stake in Purebliss to support Purebliss's financing facilities. The ₹300 crore guarantee represents ~9.3% of Anupam Rasayan's net worth (₹3,235 crore) and adds to its existing debt burden of ₹1,574 crore as a contingent liability.
Confidence: HIGH
What changedAnupam Rasayan approved extending a ₹300 crore corporate guarantee, pledging 100% equity in subsidiary MVCPL, granting a call option on MVCPL to Purebliss, and pledging its 15% stake in Purebliss.
Why it mattersThe ₹300 crore guarantee creates a significant contingent liability (~9.3% of net worth) alongside encumbering its holdings in MVCPL and Purebliss, while the call option points toward a potential future divestment of MVCPL.
Mates NCD issue size: up to INR 300 croreGuarantee vs Net Worth: ~9.3%Mates equity pledged: 100%Purebliss equity pledged: 15%
📅 Short termDefinitive agreements are yet to be executed; market attention will focus on disclosures regarding why a visa consultancy subsidiary is raising ₹300 crore and its relation to Purebliss.
📈 Long termAdds contingent liabilities to the parent balance sheet and introduces potential asset monetization or restructuring via the call option granted to Purebliss.
⚠ Risk flags
- Contingent liability of up to ₹300 crore on parent balance sheet
- Total encumbrance/pledge of shares in subsidiary MVCPL and associate Purebliss
- Unclear business rationale/end-use of funds disclosed at this stage
Key Highlights
Board approved guarantee for up to 30,000 NCDs of face value ₹1,00,000 each, aggregating up to ₹300 crore issued by subsidiary MVCPL
Pledge of 100% equity stake in Mates Visa Consultancy Private Limited in favour of the Debenture Trustee
Call option granted to Purebliss Pharma Solutions Private Limited to purchase 100% of MVCPL securities from the company
Pledge of the company's 15% equity holding in Purebliss Pharma Solutions to secure Purebliss's financing facilities
👀 What to Watch
Track the upcoming detailed Regulation 30 disclosure upon signing of definitive documents, particularly the interest rate, end-use of funds, and terms of the call option with Purebliss Pharma.
Acquires 2.6 Lakh Shares in Tanfac Industries for ₹60.88 Cr via Preferential Issue
Anupam Rasayan India Limited has acquired 2,60,065 equity shares of Tanfac Industries Limited on a preferential issue basis. The transaction was executed at ₹2,341 per share, representing an aggregate investment of ₹60.88 crore. Relative to Anupam Rasayan's net worth of ₹3,235 crore, this represents approximately 1.9%, and equals ~2.4% of its TTM revenue (₹2,535 crore). This move strengthens Anupam's strategic stake and backward integration into fluorination chemistry via Tanfac.
Confidence: HIGH
What changedTanfac Industries completed the preferential allotment of 2,60,065 shares to Anupam Rasayan following form PAS-4 execution.
Why it mattersFurther consolidates Anupam's backward integration into key raw materials for its fluorination chemistry platform.
Shares allotted: 2,60,065Issue price per share: Rs. 2,341Total consideration: Rs. 60,88,12,165Investment vs Net Worth: ~1.88%Investment vs TTM Revenue: ~2.40%
📅 Short termNeutral to slightly positive; the cash outflow of ₹60.88 crore is manageable against the existing balance sheet and expected to have minimal immediate earnings impact.
📈 Long termEnhances long-term strategic alignment with Tanfac, strengthening captive access to hydrofluoric acid (HF) and supporting high-value fluorination CDMO expansion.
⚠ Risk flags
- Capital allocation tracking against returns from associate/subsidiary operations
Key Highlights
Allotment of 2,60,065 equity shares of Tanfac Industries completed
Acquisition price of ₹2,341 per share with face value of ₹5 each
Aggregate investment consideration of ₹60,88,12,165 (~₹60.88 crore)
Investment represents ~1.9% of net worth and ~2.4% of TTM revenue
👀 What to Watch
Track the updated shareholding pattern of Tanfac Industries to evaluate Anupam's expanded control, alongside synergies in HF capacity utilization.
Anupam Rasayan to Invest ₹60.88 Cr to Acquire 0.73% Additional Stake in Tanfac Industries
Anupam Rasayan's board has approved the acquisition of 2,60,065 equity shares in its subsidiary, Tanfac Industries Limited, via a preferential issue. The investment totals ₹60.88 crore at an issue price of ₹2,341 per share, representing approximately 0.73% of Tanfac's post-issue paid-up equity capital. The transaction aims to restore Anupam's stake following passive dilution from Tanfac's recent qualified institutional placement (QIP). Relative to Anupam's balance sheet, this ₹60.88 crore cash outlay is modest, equaling ~1.88% of net worth and ~2.4% of TTM revenue.
Confidence: HIGH
What changedAnupam Rasayan agreed to subscribe to 2,60,065 shares of Tanfac Industries on a preferential basis for ₹60.88 crore.
Why it mattersProtects Anupam's ownership position and control in its key backward-integrated fluorination platform partner after recent institutional dilution.
Total Consideration: Rs. 60,88,12,165Issue Price per Share: Rs. 2,341Shares Acquired: 2,60,065Post-Issue Stake Acquired: 0.73%Investment vs TTM Revenue: ~2.4%Investment vs Net Worth: ~1.9%
📅 Short termNeutral market impact expected as the cash outlay of ₹60.88 crore is small and allotment is slated to conclude rapidly by September 09, 2026.
📈 Long termReaffirms Anupam's commitment to Tanfac as a core backward-integration vehicle for its high-value fluorination chemistry portfolio.
Key Highlights
Board approved acquisition of 2,60,065 equity shares of Tanfac Industries at ₹2,341 per share.
Total cash consideration is ₹60,88,12,165 (approx. ₹60.88 crore).
Acquisition represents approximately 0.73% of post-issue paid-up equity capital of Tanfac.
Target company Tanfac reported FY26 turnover of ₹711.10 crore and net worth of ₹373.2 crore.
Tentative completion date for share allotment is September 09, 2026.
👀 What to Watch
Track the confirmation of allotment scheduled for September 09, 2026, and Tanfac's subsequent financial disclosures to assess the combined operational progress in fluorination.
Anupam Rasayan to Invest ₹60.88 Cr in Tanfac Industries via Preferential Issue; Fixes Dividend Dates
Anupam Rasayan's board has approved the acquisition of 2,60,065 equity shares of Tanfac Industries Limited on a preferential issue basis for ₹60.88 Cr at an issue price of ₹2,341 per share. The investment represents ~2.4% of Anupam's TTM revenue (₹2,535 Cr) and strengthens its backward integration in fluorination chemistry. Additionally, the company set September 18, 2026, as the record date for the FY26 final dividend and scheduled its 23rd AGM for September 30, 2026. Ms. Hetvi Vyas was also appointed as Deputy Chief Financial Officer and Key Managerial Personnel.
Confidence: HIGH
What changedApproved an incremental ₹60.88 Cr equity investment in Tanfac Industries and scheduled the 23rd AGM along with setting the FY26 final dividend record date.
Why it mattersDeepens Anupam Rasayan's strategic ownership and backward integration in key fluorination raw materials via Tanfac, supporting long-term margins and chemistry capabilities.
Tanfac Investment Value: Rs. 60,88,12,165Issue Price per Share: Rs. 2,341Shares to be Acquired: 2,60,065Investment vs TTM Revenue: ~2.4%Dividend Record Date: September 18, 2026
📅 Short termTrading will reflect standard dividend cut-off adjustments around the September 18 record date, while the incremental ₹60.88 Cr cash outflow is modest relative to Anupam's balance sheet.
📈 Long termReinforces Anupam Rasayan's positioning as an integrated fluorination player, aiding higher-value CDMO and polymer chemical contracts over coming years.
⚠ Risk flags
- Cash outflow towards associate/subsidiary preferential issue amidst existing debt of ₹1,574 Cr
Key Highlights
Board approved acquisition of 2,60,065 equity shares (face value ₹5) of Tanfac Industries at ₹2,341 per share
Total preferential issue investment consideration stands at ₹60,88,12,165 (~₹60.88 Cr)
Record date for payment of final dividend for FY 2025-26 fixed as Friday, September 18, 2026
23rd Annual General Meeting scheduled for Wednesday, September 30, 2026
Appointed Ms. Hetvi Vyas as Deputy Chief Financial Officer and Key Managerial Personnel
👀 What to Watch
Track shareholder approvals at the upcoming AGM on September 30, 2026, and monitor Tanfac's capacity ramp-up as Anupam expands its integrated fluorination platform.
Anupam Rasayan Signs 6-Year Chemical Supply Contract with US Specialty Metal Major
Anupam Rasayan India Limited has entered into a 6-year long-term supply contract with a US-headquartered global specialty metal major. The contract covers the supply of a specialty chemical product to support the client's global operations. Commercial dispatches under the agreement are scheduled to begin from the latter half of Q3 FY27. Total consideration is volume-linked and not quantified in the filing.
Confidence: HIGH
What changedAnupam Rasayan signed a 6-year specialty chemical supply agreement with a US industrial major, diversifying beyond its traditional client base.
Why it mattersProvides multi-year revenue visibility and strengthens the company's international custom synthesis portfolio starting in FY27.
Contract duration: 6 yearsDispatch timeline: Latter half of Q3 FY27Order value: not disclosedTotal installed capacity: ~2,00,000+ MT
📅 Short termPositive for sentiment, though revenue contribution will only start in late FY27.
📈 Long termAdds multi-year order visibility and expands custom manufacturing into the global geological resource and specialty metals domain.
⚠ Risk flags
- Order value not quantified (volume-linked pricing)
- Execution lead time with dispatches starting only from Q3 FY27
Key Highlights
Signed a 6-year multi-year supply contract with a US-based specialty metal manufacturer
Commercial dispatches expected to commence from the second half of Q3 FY27
Marks entry and diversification into the geological resource sector segment
Aggregate manufacturing capacity across 8 facilities stands at ~2,00,000+ MT as of March 31, 2026
👀 What to Watch
Track management commentary in upcoming earnings calls regarding revenue potential and margin profile of this contract, as well as readiness for dispatches starting Q3 FY27.
CRISIL Keeps Anupam Rasayan's Rs 1,780 Cr Debt on Watch Developing on Bliss GVS Acquisition
CRISIL Ratings has maintained its 'CRISIL A+/Watch Developing' rating on Anupam Rasayan's Rs 1,620 crore bank facilities and Rs 160 crore non-convertible debentures. The rating watch reflects the pending acquisition of a 43.3% to 48.2% stake in Bliss GVS Pharma, targeted for completion in September 2026. CRISIL noted that ARIL will fund the acquisition through Rs 300 crore in fresh debt alongside non-voting equity from a global fund, limiting expected rating movement to at most one notch. Liquidity remains strong with FY27 projected cash accruals of Rs 280-350 crore against debt repayments of Rs 40 crore.
Confidence: HIGH
What changedCRISIL has continued its credit ratings on 'Rating Watch with Developing Implications' pending the final funding closure of ARIL's stake purchase in Bliss GVS Pharma.
Why it mattersConfirms the acquisition's debt footprint will be limited to ~Rs 300 crore (~11.8% of TTM revenue), containing leverage escalation and rating downgrade risks.
Total rated bank facilities: Rs 1620 CroreRated NCDs: Rs 160 CroreAcquisition debt addition: Rs 300 croreAcquisition debt vs TTM revenue: ~11.8%FY27 expected cash accrual: Rs 280-350 croreCash and equivalents (March 31, 2026): > Rs 378 crore
📅 Short termWatch resolution expected in September-October 2026 once the Bliss GVS transaction and funding approvals conclude.
📈 Long termIf successfully integrated alongside Jayhawk Fine Chemicals, the acquisition expands pharma formulation exposure and cushions agrochemical cyclicality.
⚠ Risk flags
- Integration and debt burden from the Bliss GVS Pharma acquisition
- High working capital intensity despite recent improvements in inventory days
Key Highlights
CRISIL reaffirmed 'CRISIL A+/Watch Developing' on Rs 1,620 Cr bank facilities and Rs 160 Cr NCDs.
Company to incur Rs 300 Cr debt to fund the Bliss GVS Pharma acquisition, with remainder from a global fund.
Acquisition of 43.3-48.2% stake in Bliss GVS Pharma is expected to close in September 2026.
Expected FY27 net cash accrual is Rs 280-350 Cr against debt repayment obligations of Rs 40 Cr.
Inventory days improved to 324 days as of March 31, 2026, down from 510 days a year prior.
👀 What to Watch
Track the formal completion and exact funding mix of the Bliss GVS Pharma transaction in September 2026 to see if CRISIL resolves the watch without a rating downgrade.
Anupam Rasayan Q1 FY27 Concall: 36% YoY Revenue Growth, USD 300M LOI with BASQUEVOLT
Anupam Rasayan released its Q1 FY27 earnings call transcript, highlighting a 36% YoY increase in consolidated total income. The company announced the global first commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry and signed an LOI with BASQUEVOLT representing a ~USD 300 million (~INR 2,500 Cr) opportunity over 10 years. Total cumulative signed LOIs and contracts now stand at ~INR 18,000 Cr (approx. 7.1x TTM revenue). Management also reiterated progress on the integration of Jayhawk Fine Chemicals and the pending acquisition of Bliss GVS Pharma.
Confidence: HIGH
What changedSubmission of the detailed transcript from the Q1 FY27 earnings conference call held on August 14, 2026.
Why it mattersProvides visibility into the execution of the INR 18,000 Cr contract pipeline, technological advances in flow chemistry, and margin synergies from global acquisitions.
Q1 FY27 YoY Income Growth: 36%BASQUEVOLT LOI Potential: ~USD 300 million (~INR 2,500 Cr)BASQUEVOLT LOI vs TTM Revenue: ~99% (over 10 years)Cumulative Signed LOIs and Contracts: INR 18,000 croresOrder pipeline vs TTM Revenue: ~7.1x
📅 Short termThe commentary confirms steady operational traction and new product launches (ETFA via flow chemistry), providing confidence in the ongoing FY27 performance.
📈 Long termIntegration of Jayhawk and Bliss GVS along with backward integration via Tanfac positions the company as a full-suite global CDMO/specialty chemicals platform.
⚠ Risk flags
- M&A execution and integration risks across overseas and domestic acquisitions
- Dependence on global automotive/EV demand for scale-up of new contracts
Key Highlights
Consolidated total income grew 36% YoY in Q1 FY27
Signed an LOI with BASQUEVOLT with a potential value of ~USD 300 million over 10 years
Cumulative signed contracts and LOIs reach ~INR 18,000 crores across long-term tenures
Pipeline includes 65+ pharma and polymer molecules in R&D and pilot stages
👀 What to Watch
Track the commercialization timeline of the BASQUEVOLT contract starting in FY27 and the closure/integration milestones of the Bliss GVS Pharma acquisition.
₹2,850 Cr LOI and 36% Revenue Growth in Q1 FY27 Investor Presentation
Anupam Rasayan reported a strong 36% YoY increase in consolidated revenue to ₹667.5 Cr for Q1 FY27, driven by new product commercialization. A major highlight is a new 10-year Letter of Intent (LOI) with BASQUEVOLT, S.A. valued at approximately $300 million (₹2,850 Cr), which exceeds the company's total TTM revenue. While EBITDA grew 35% to ₹174.9 Cr, PAT growth was limited to 6% (₹51.2 Cr) due to a 57% increase in depreciation and a 38% rise in finance costs. The company is also progressing with the ₹1,600 Cr acquisition of Bliss GVS Pharma to bolster its pharmaceutical CDMO platform.
Confidence: HIGH
What changedThe company reported its Q1 FY27 results and announced a massive new long-term supply agreement alongside updates on its pharmaceutical acquisition strategy.
Why it mattersThe new ₹2,850 Cr LOI provides significant long-term revenue visibility, while the shift toward pharmaceutical and polymer CDMO (now 125+ products) aims to improve margins and reduce cyclicality.
Q1 FY27 Consolidated Revenue: ₹667.5 CrNew LOI Value: ₹2,850 CrLOI vs TTM Revenue: 112.4%Total Order Book: ₹17,496 CrBliss GVS Acquisition Cost: ₹1,600 CrConsolidated EBITDA Margin: 26%
📅 Short termThe stock may react positively to the strong top-line growth and the substantial new order win, though high interest costs remain a drag on the bottom line.
📈 Long termThe company is structurally pivoting toward high-value fluorination and pharma CDMO, supported by a massive order book that is nearly 7x its TTM revenue.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High finance costs (₹49.2 Cr in Q1)
- Execution risk of the ₹17,496 Cr order book
- Integration risk of the Bliss GVS Pharma acquisition
Key Highlights
Signed a 10-year LOI with BASQUEVOLT, S.A. worth approximately ₹2,850 Cr ($300 million) for specialty chemicals.
Consolidated revenue grew 36% YoY to ₹667.5 Cr, while Standalone revenue grew 4% to ₹334.9 Cr.
Total order book and LOIs reached a cumulative value of ₹17,496 Cr as of Q1 FY27.
Proposed acquisition of Bliss GVS Pharma for ~₹1,600 Cr is progressing to strengthen the pharma CDMO segment.
Became the first company globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
👀 What to Watch
Watch for the successful completion of the Bliss GVS Pharma acquisition and the commercialization timeline of the BASQUEVOLT LOI, which is expected to start contributing in FY27.
36% Revenue Growth in Q1 FY27; ~$300M LoI Signed with BASQUEVOLT
Anupam Rasayan reported a strong 36% YoY revenue growth to Rs 667.5 Cr for Q1 FY27, driven by momentum in its specialty chemicals and CDMO platform. While EBITDA grew 35% to Rs 174.9 Cr with healthy margins of 26.2%, PAT growth was relatively muted at 6% YoY (Rs 51.2 Cr). A major highlight is the signing of a ~$300M (approx. Rs 2,500 Cr) Letter of Intent with BASQUEVOLT for a 10-year supply, which is nearly equivalent to the company's total TTM revenue. Additionally, the company became the first globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
Confidence: HIGH
What changedAnupam Rasayan reported its Q1 FY27 financial results and announced a significant long-term supply agreement alongside a technological milestone in flow chemistry.
Why it mattersThe ~$300M LoI provides long-term revenue visibility and validates the company's strategy in performance materials, while the ETFA commercialization demonstrates high-end R&D capabilities in complex fluorination.
Q1 FY27 Revenue: Rs 667.5 CrYoY Revenue Growth: 36%LoI Value: ~$300 millionLoI vs TTM Revenue: ~98.6%EBITDA Margin: 26.2%PAT Growth: 6%
📅 Short termThe stock is likely to react positively to the strong top-line growth and the massive $300M LoI announcement, which offsets the slower PAT growth.
📈 Long termThe company is structurally positioning itself as a high-tech CDMO player through its fluorination platform and U.S. footprint, with the BASQUEVOLT deal providing a decade of revenue tailwinds.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Muted PAT growth compared to revenue
- Execution risk on the large 10-year LoI
- High debt levels (Rs 1,574 Cr) relative to quarterly earnings
Key Highlights
Total Revenue for Q1 FY27 increased 36% YoY to Rs 667.5 Cr from Rs 490.7 Cr
Signed a ~$300M (Rs 2,500 Cr) Letter of Intent with BASQUEVOLT for a 10-year supply period
EBITDA grew 35% YoY to Rs 174.9 Cr with a stable margin of 26.2%
Commercialized Ethyl Trifluoroacetate (ETFA) using flow chemistry, a global first for this product
Total installed capacity reached 200,000+ MT across 8 manufacturing facilities as of March 2026
👀 What to Watch
Monitor the conversion of the BASQUEVOLT LoI into a definitive contract and the execution timeline for the Bliss GVS Pharma acquisition. Investors should also track if the high-value ETFA product helps improve net margins, which lagged revenue growth this quarter.
Anupam Rasayan Appoints Ravi Desai as COO to Oversee ₹8,919 Cr Order Book
Anupam Rasayan has promoted Mr. Ravi Desai to the position of Chief Operating Officer (COO) effective August 14, 2026. Mr. Desai, who previously served as the Sales Head, has been with the company since 2012 and possesses over 20 years of experience in the specialty chemicals industry. This internal appointment is strategic as the company scales operations to execute its significant ₹8,919 Cr order book and integrates the $150 million Jayhawk acquisition. His role will focus on aligning sales, manufacturing, and R&D to enhance operational efficiency.
Confidence: HIGH
What changedInternal promotion of the existing Sales Head, Mr. Ravi Desai, to the role of Chief Operating Officer.
Why it mattersEnsures leadership continuity and integrates sales strategy with plant operations during a high-growth phase where revenue reached ₹2,366 Cr in FY26.
Order Book: ₹8,919 CrIndustry Experience: 20+ yearsCompany Tenure: 14 yearsTTM Revenue: ₹2,366 Cr
📅 Short termNeutral; the market typically views internal promotions as a sign of stability rather than a catalyst for immediate price movement.
📈 Long termPositive for operational execution as the new COO has deep institutional knowledge across both sales and manufacturing functions.
Key Highlights
Appointment of Mr. Ravi Desai as COO effective August 14, 2026
Mr. Desai brings over 20 years of extensive experience in specialty chemicals
Internal promotion of the existing Sales Head who has been with the firm since 2012
Company is currently managing a massive order book of ₹8,919 Cr
The appointee will continue as a Key Managerial Personnel (KMP) of the company
👀 What to Watch
Monitor if this leadership transition leads to improved execution of the ₹8,919 Cr order book and stabilization of operating margins, which stood at 22.2% in FY26.
₹32.0 Cr Standalone PAT in Q1 FY27; Ravi Desai Appointed as COO
Anupam Rasayan reported standalone revenue of ₹328.8 cr for Q1 FY27, a 4.2% increase YoY from ₹315.7 cr, but an 11.3% sequential decline from Q4 FY26. Standalone PAT stood at ₹32.0 cr, up 7.8% YoY from ₹29.7 cr, though it fell 24.5% from the previous quarter's ₹42.4 cr. Finance costs rose significantly to ₹42.1 cr from ₹33.7 cr in the year-ago period. The company also appointed Ravi Desai as Chief Operating Officer (COO) and confirmed the liquidation of its step-down subsidiary, Monitchem Kansas S.a.r.l.
Confidence: HIGH
What changedRelease of Q1 FY27 standalone financial results and the appointment of a new Chief Operating Officer.
Why it mattersThe results show stable year-on-year performance but highlight sequential pressure and a rising interest burden, which investors must weigh against the company's long-term fluorination growth strategy.
Standalone Revenue (Q1 FY27): ₹328.8 crStandalone PAT (Q1 FY27): ₹32.0 crFinance Costs (Q1 FY27): ₹42.1 crQ1 Revenue vs TTM Revenue: ~13.9%YoY Revenue Growth: 4.2%
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the sequential decline in revenue and profit despite the YoY growth.
📈 Long termStructural growth remains tied to the successful integration of the Jayhawk acquisition and the expansion of the high-value fluorination platform.
⚠ Risk flags
- Rising finance costs
- Sequential revenue decline
- Agrochemical sector demand pressure
Key Highlights
Standalone Revenue from Operations reached ₹328.8 cr in Q1 FY27 vs ₹315.7 cr in Q1 FY26.
Standalone Profit After Tax (PAT) reported at ₹32.0 cr for the quarter.
Finance costs increased by 24.9% YoY to ₹42.1 cr, impacting net margins.
Ravi Desai appointed as Chief Operating Officer effective August 14, 2026.
Step-down subsidiary Monitchem Kansas S.a.r.l liquidated effective June 30, 2026.
👀 What to Watch
Monitor the impact of the new COO on operational efficiency and the progress of the ₹8,919 cr order book execution amidst rising finance costs.
₹829 Cr Open Offer: Anupam Rasayan to acquire 26% stake in Bliss GVS Pharma
Anupam Rasayan has issued a formal Letter of Offer to acquire up to 2.77 crore shares (26% stake) of Bliss GVS Pharma Limited. The offer is priced at ₹299 per share, implying a total cash consideration of approximately ₹829 crore. This transaction is significant, representing roughly 35% of Anupam Rasayan's TTM revenue and 25.6% of its net worth. The acquisition is being made alongside Mates Visa Consultancy as a Person Acting in Concert (PAC).
Confidence: HIGH
What changedAnupam Rasayan has progressed from the initial announcement to the formal 'Letter of Offer' stage for a significant minority stake in Bliss GVS Pharma.
Why it mattersThis represents a major strategic expansion into the pharmaceutical sector, utilizing a substantial portion of the company's balance sheet (approx. 25% of net worth) to diversify its life sciences portfolio.
Offer Price per Share: ₹299.00Maximum Shares to Acquire: 2,77,26,848Stake Percentage: 26.00%Estimated Deal Value: ₹829.03 CrDeal Value vs TTM Revenue: ~35%Deal Value vs Net Worth: ~25.6%
📅 Short termThe stock may experience volatility as the market assesses the high cash outflow and the strategic fit of Bliss GVS Pharma within Anupam's existing chemical operations.
📈 Long termIf successfully integrated, this could provide Anupam Rasayan with deeper forward integration into the pharma value chain, though it increases the complexity of the business model.
⚠ Risk flags
- Significant cash outflow of ₹829 crore
- Potential increase in debt-to-equity ratio (currently 0.49)
- Integration risk of a pharmaceutical target into a specialty chemical business
Key Highlights
Open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited.
Offer price fixed at ₹299.00 per share, to be paid in cash.
Acquisition represents 26.00% of the expanded voting share capital of the target company.
Total potential deal value estimated at ₹829.03 crore based on the offer price and share count.
Anupam Rasayan's TTM revenue is ₹2,366 crore, making this acquisition a major capital allocation move.
👀 What to Watch
Monitor the tendering period dates and the final acceptance ratio to see if Anupam Rasayan successfully reaches the 26% threshold. Investors should also watch for management's guidance on how this acquisition will be funded given the existing debt of ₹1,574 crore.
$300 Million LOI signed with BASQUEVOLT for battery specialty chemicals
Anupam Rasayan has signed a non-binding Letter of Intent (LOI) with Spain-based BASQUEVOLT for the potential supply of specialty chemicals for solid-state lithium batteries. The deal is valued at $300 million (approx. ₹2,500 Cr) over a 10-year period, representing a significant entry into the EV battery materials space. On an annualized basis, the potential revenue of ~$30 million (₹250 Cr) would contribute roughly 10.5% to the company's TTM revenue of ₹2,366 Cr. However, investors should note the LOI is currently non-binding and contingent on successful product development and a definitive agreement.
Confidence: HIGH
What changedAnupam Rasayan has secured a preliminary long-term supply commitment in the EV battery chemical space, moving beyond its traditional agrochemical and pharma focus.
Why it mattersThis marks a strategic diversification into high-value electronic chemicals, which could potentially offer higher margins and a more stable long-term revenue stream compared to cyclical agrochemicals.
Potential Order Value: $300 MillionContract Duration: 10 yearsAnnualized Value vs TTM Revenue: ~10.5%Total Value vs TTM Revenue: ~105%Existing Order Book: ₹8,919 Cr
📅 Short termThe stock may see positive sentiment due to the large headline value, though the non-binding nature of the LOI means immediate financial impact is nil.
📈 Long termIf commercialized, this provides a decade-long revenue visibility in a high-tech sector, supporting the company's 20-25% growth guidance.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Non-binding agreement
- Product development risk
- Long execution timeline
- Customer concentration in a niche technology (solid-state batteries)
Key Highlights
Potential cumulative revenue of $300 million over a 10-year supply period
Strategic partnership with BASQUEVOLT, S.A., a European developer of solid-state lithium batteries
Focuses on the high-growth electronic chemicals and EV battery domain
LOI is non-binding and subject to successful product development and definitive contract negotiation
Adds to an existing robust order book which stood at ₹8,919 Cr as per recent filings
👀 What to Watch
Monitor for the conversion of this non-binding LOI into a definitive supply agreement and updates on the product development timeline for the solid-state battery chemicals.
